Role of TGF-β signaling pathway on Tenascin C protein upregulation in a pilocarpine seizure model

Epilepsy Res. 2014 Dec;108(10):1694-704. doi: 10.1016/j.eplepsyres.2014.09.019. Epub 2014 Oct 19.

Abstract

Seizures have been shown to upregulate the expression of numerous extracellular matrix molecules. Tenascin C (TNC) is an extracellular matrix protein involved in several physiological roles and in pathological conditions. Though TNC upregulation has been described after excitotoxins injection, to date there is no research work on the signal transduction pathway(s) participating in TNC protein overproduction. The aim of this study was to evaluate the role of TGF-β signaling pathway on TNC upregulation. In this study, we used male rats, which were injected with saline or pilocarpine to induce status epilepticus (SE) and killed 24h, 3 and 7 days after pilocarpine administration. For evaluating biochemical changes, we measured protein content of TNC, TGF-β1 and phospho-Smad2/3 for localization of TNC in coronal brain hippocampus at 24h, 3 and 7 days after pilocarpine-caused SE. We found a significant increase of TNC protein content in hippocampal homogenates after 1, 3, and 7 days of pilocarpine-caused SE, together with an enhancement of TNC immunoreactivity in several hippocampal layers and the dentate gyrus field where more dramatic changes occurred. We also observed a significant enhancement of protein content of both the TGF-β1 and the critical downstream transduction effector phospho-Smad2/3 throughout the chronic exposure. Interestingly, animals injected with SB-431542, a TGF-β-type I receptor inhibitor, decreased TNC content in cytosolic fraction and diminished phospho-Smad2/3 content in both cytoplasmic and nuclear fraction compared with pilocarpine vehicle-injected. These findings suggest the participation of TGF-β signaling pathway on upregulation of TNC which in turn support the idea that misregulation of this signaling pathway produces changes that may contribute to disease.

Keywords: Hippocampus; Phospho-Smad2/3; Pilocarpine; Status epilepticus; Tenascin C; Transforming growth factor β.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzamides / pharmacology
  • Cell Nucleus / drug effects
  • Cell Nucleus / metabolism
  • Central Nervous System Agents / pharmacology
  • Cytoplasm / drug effects
  • Cytoplasm / metabolism
  • Dioxoles / pharmacology
  • Disease Models, Animal
  • Hippocampus / drug effects
  • Hippocampus / metabolism*
  • Male
  • Phosphorylation
  • Pilocarpine
  • Protein Serine-Threonine Kinases / metabolism*
  • Rats, Wistar
  • Receptor, Transforming Growth Factor-beta Type I
  • Receptors, Transforming Growth Factor beta / metabolism*
  • Seizures / metabolism*
  • Signal Transduction / drug effects
  • Smad2 Protein / metabolism
  • Smad3 Protein / metabolism
  • Tenascin / metabolism*
  • Transforming Growth Factor beta / antagonists & inhibitors
  • Transforming Growth Factor beta / metabolism*
  • Up-Regulation / drug effects

Substances

  • 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide
  • Benzamides
  • Central Nervous System Agents
  • Dioxoles
  • Receptors, Transforming Growth Factor beta
  • Smad2 Protein
  • Smad2 protein, rat
  • Smad3 Protein
  • Smad3 protein, rat
  • Tenascin
  • Transforming Growth Factor beta
  • Pilocarpine
  • Protein Serine-Threonine Kinases
  • Receptor, Transforming Growth Factor-beta Type I
  • Tgfbr1 protein, rat